| Document |
Document Title |
|
WO/2023/196746A1 |
The present disclosure provides a method of restoring or enhancing visual function in an individual, the method comprising administering to the individual nucleic acids comprising nucleotide sequences encoding a medium wavelength cone op...
|
|
WO/2023/196842A1 |
Provided herein are pharmaceutical compositions for administration to a suprachoroidal space of an eye of a subject. The pharmaceutical compositions can include a recombinant adeno- associated virus (AAV) encoding a transgene. Also provi...
|
|
WO/2023/196873A1 |
Provided herein are pharmaceutical compositions for administration to a suprachoroidal space of an eye of a subject. The pharmaceutical compositions can include a recombinant adeno- associated virus (AAV) encoding a transgene. Also provi...
|
|
WO/2022/251484A9 |
Inappropriate or excessive complement activation is an underlying cause or contributing factor to a number of serious diseases and conditions, and considerable effort has been devoted over the past several decades to exploring various co...
|
|
WO/2023/196234A1 |
Disclosed herein are methods, devices, and systems for treating lens protein aggregation diseases by reducing the formation of proteins responsible for crowding, compacting, and/or causing increased internal lens pressure. Specifically d...
|
|
WO/2023/185231A1 |
The present application provides methods for editing RNA by introducing a deaminase-recruiting RNA in a host cell for deamination of an adenosine in a target RNA encoding a mutant Usher 2A protein. The present application further provide...
|
|
WO/2023/192828A2 |
Provided herein are compositions comprising an oligonucleotide that targets ANGPTL7. In some embodiments, the oligonucleotide includes modified nucleotides. In some embodiments, the oligonucleotide may be used to reduce intraocular press...
|
|
WO/2023/185634A1 |
The present application relates to the field of medicine, and particularly discloses a compound of formula (I), a preparation method therefor, and use of said compound in the preparation of a drug for treating plasma kallikrein-mediated ...
|
|
WO/2023/190663A1 |
The present invention provides an effective production method and/or purification method for a high-yield and high-purity (R)-11-[[-[(diethylamino)methyl]-1-piperidinyl]-acetyl]-5,11
-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine-6-one or ...
|
|
WO/2023/187715A1 |
Provided herein are compounds of formula (I) and pharmaceutical compositions thereof useful for treating diseases or disorders mediated by the complement factor B.
|
|
WO/2023/192691A2 |
In various aspects, methods and formulations are provided for treating subjects, in particular mammals, intranasally with an effective amount of insulin, an insulin analog, or an insulin derivative to treat or prevent an eye disease, in ...
|
|
WO/2023/186131A1 |
Provided are a bispecific antibody, an encoding nucleic acid thereof, an AAV virus vector containing the nucleic acid, and a virus particle. Further provided is a pharmaceutical composition containing the bispecific antibody, the encodin...
|
|
WO/2023/191606A1 |
The present invention relates to amniotic epithelial cell-derived extracellular vesicles (EVs) which encapsulate a drug for ophthalmic diseases, and the EVs contain sub-ingredients for drug dissolution, thus remarkably reducing eye toxic...
|
|
WO/2023/187783A1 |
Newly designed compounds represented by Formulae I-V as described in the instant specification and uses thereof as pancreatic endoplasmic reticulum kinase (PERK) activators and in treating associated medical conditions, including viral i...
|
|
WO/2023/190707A1 |
[Problem] To clarify the mechanism of the medial olivocochlear (MOC) feedback system and provide a composition for preventing or treating auditory disorders in which MOC neurons participate. To provide a method for screening a compound f...
|
|
WO/2023/190941A1 |
The present disclosure provides: a method for washing corneal endothelial cells; and a method for producing a corneal endothelial cell preparation. In one aspect, the present disclosure provides a method for producing a corneal endotheli...
|
|
WO/2023/190653A1 |
The present invention provides a pharmaceutical preparation in which an aqueous pharmaceutical composition, which contains (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,
11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one o...
|
|
WO/2023/190809A1 |
The present invention addresses the problem of providing: a new food component that inhibits production of cortisol; and a composition containing the food component. The present invention provides a composition that is for inhibiting p...
|
|
WO/2023/192935A1 |
Methods for treating diabetic retinopathy and age-related macular degeneration (AMD), as well as pharmaceutical compositions relevant thereto are disclosed.
|
|
WO/2023/190568A1 |
The present invention provides an osmotic pressure regulating agent that contains allitol or a pharmaceutically acceptable salt thereof. The present invention also provides a transfusion, a peritoneal dialysate, an ophthalmic composition...
|
|
WO/2023/187198A1 |
The present invention relates to the use of the HIP/PAP protein, or a derivative thereof, for treating and/or preventing, in an individual in need thereof, a disorder characterized by a CXCL5 level higher in a biological sample of said i...
|
|
WO/2023/182871A1 |
The present invention relates to a 3-phenylisoxazole derivative, a preparation method therefor, and a pharmaceutical composition for preventing or treating eye disease, containing same as an active ingredient. The 3-phenylisoxazole deriv...
|
|
WO/2023/180454A2 |
The present invention relates to a synthetic peptide analog of the Preimplantation factor (PIF) peptide with a sequence length of maximum 20 amino acids consisting in the sequence Xaa1 Xaa2 R3 I4 K5 P6 Xaa7-20 (SEQ ID No1): wherein Xaa c...
|
|
WO/2023/182480A1 |
A first invention pertains to an aqueous composition that contains (A) 4-phenylbutyric acid or an ester thereof, or a pharmacologically acceptable salt thereof, and that is housed in a container in which all or a portion thereof in conta...
|
|
WO/2023/182606A1 |
The present invention relates to a novel compound that induces the expression of the anti-aging gene klotho. The compound according to the present invention is superb in terms of enhancing the expression level of the senescence-associate...
|
|
WO/2023/183153A1 |
A combination therapy including both intranasal and oral solid-form preparations is described. In combination, the intranasal and oral delivery pathways provided an enhancement in appetite suppression and associated weight loss in compar...
|
|
WO/2023/183556A2 |
Compositions in the treatment of retinal disorders include a phosphorothioate oligonucleotide in a therapeutically effective amount. The phosphorothioate oligonucleotide is administered in the treatment of retinal disorders.
|
|
WO/2023/182735A1 |
The present invention relates to a composition for preventing or treating macular degeneration, comprising a compound that induces the expression of anti-aging gene klotho. The compound according to the present invention has an excellent...
|
|
WO/2023/178386A1 |
The present disclosure generally relates to methods of treating, preventing and/or delaying progression of glaucoma in a subject, the method comprising administering an antisense oligonucleotide that modulates mRNA productive transcript,...
|
|
WO/2023/178160A1 |
The present disclosure describes compositions that can be used in the treatment of an ocular injury or disease in a subject in need thereof. Methods of preparing the compositions are also described. The compositions can include one or mo...
|
|
WO/2023/176720A1 |
Provided is a retinal vasodilator containing nobiletin. Also provided is a pharmaceutical composition for treating or preventing retinal circulatory disorders, the composition containing said retinal vasodilator and a pharmaceutically ac...
|
|
WO/2023/175078A1 |
The present invention relates to azasetron or an analog of azasetron, or a pharmaceutically acceptable salt and/or solvate thereof, for use in the treatment of severe or profound sudden sensorineural hearing loss (SSNHL) in a subject in ...
|
|
WO/2023/177689A1 |
The present invention relates to regimens for the treatment of angiogenic eye disorders such as DR and DME characterized by high doses of aflibercept and lengthening intervals between doses.
|
|
WO/2023/177691A1 |
The present invention relates to regimens for the treatment of angiogenic eye disorders such as nAMD, characterized by high doses of aflibercept and extended intervals between doses.
|
|
WO/2023/176977A1 |
Provided is a method capable of industrially advantageously manufacturing a labiatae extract containing a rosmarinic acid at a high concentration. The method for manufacturing a labiatae hot-water extract comprises steps (A) and (B): (...
|
|
WO/2023/176879A1 |
The present invention addresses the problem of providing a pharmaceutical composition for use in prevention or treatment of lifestyle related diseases including type-2 diabetes and obesity related diseases. As a solution to the problem...
|
|
WO/2023/173846A1 |
A steroid compound and a pharmaceutically acceptable salt thereof, a preparation method therefor and the use thereof. The structural formula of the steroid compound is as shown in formula I', wherein R is dimethylamino or methylamino. Th...
|
|
WO/2023/173088A1 |
This invention relates to a method for preventing, stabilizing or slowing progression of AMD in an eye in a human subject comprising administering to the eye an ocular drug delivery insert.
|
|
WO/2023/171806A1 |
The present invention provides a novel therapeutic or prophylactic agent that can treat or prevent diseases associated with mitochondrial dysfunctions. The present invention provides a therapeutic or prophylactic agent for diseases assoc...
|
|
WO/2023/171989A1 |
The present invention relates to a pharmaceutical composition for preventing or treating eye diseases, and a method for preventing or treating eye diseases by using same, and, more specifically, provides a pharmaceutical composition for ...
|
|
WO/2023/173086A1 |
Described herein are compositions and method for expressing therapeutics. The compositions comprise engineered polypeptides comprising a natriuretic peptide connected to an antibody or fragment thereof. AAV vectors encoding said engineer...
|
|
WO/2023/173120A1 |
Described herein are systems and methods for modulating gene expression. Also described herein are systems and methods for treating a disease or a condition by modulating gene expression.
|
|
WO/2023/172995A1 |
Described herein are systems and methods for modulating gene expression. Also described herein are systems and methods for treating a disease or a condition by modulating gene expression.
|
|
WO/2023/171360A1 |
An administration device (10) and an administration method comprise: a tubular body (12) that has a lumen (12c) having a curved shape configured to conform to a gap between the eye surface and eye lid and that holds therein a substance t...
|
|
WO/2023/173095A1 |
This invention relates to a method of treating posterior ocular conditions in an eye in a human subject comprising administering to the eye an ocular drug delivery insert.
|
|
WO/2023/172294A1 |
This disclosure is directed to ophthalmic suspension vehicles for delivery of at least one pharmaceutical ingredient to a patient in need of treatment. The disclosure also provides methods of delivering at least one pharmaceutical ingred...
|
|
WO/2023/168898A1 |
A traditional Chinese medicine composition and an application thereof. The traditional Chinese medicine composition is prepared from grassleaf sweetflag rhizome, cassia seed, desertliving cistanche, root of lobed kudzuvine, plumed cocksc...
|
|
WO/2023/169163A1 |
The present invention relates to the technical field of eye drug preparation. Aiming at the problem that complications may be caused by the current prevention and treatment means for corneal neovascularization, the present invention prov...
|
|
WO/2023/172240A1 |
The present disclosure encompasses methods and compositions for extended-release formulations for treating ophthalmic conditions. These formulations comprise a pharmaceutical agent, a cationic polymer, a non-ionic polymer, and a pharmace...
|
|
WO/2023/167518A1 |
The present invention relates to: a composition for preventing, alleviating or treating dry eye syndrome or meibomian gland dysfunction; and the like, and was completed by identifying the excellent effects of treating dry eye syndrome wi...
|
